Core Viewpoint - Teabo Bio's performance continues to grow significantly in the hepatitis B field, with a strong increase in revenue and net profit in Q1 2025 compared to the previous year [1][2]. Financial Performance - In Q1 2025, Teabo Bio achieved revenue of 673 million yuan, a year-on-year increase of 23.48%, and a net profit of 182 million yuan, up 41.4% [1]. - From 2020 to 2024, the company's revenue grew from 794 million yuan to 2.817 billion yuan, while net profit increased from 117 million yuan to 828 million yuan [2]. - The company has maintained a continuous dual increase in revenue and net profit for seven consecutive years, with a cumulative net profit of 1.968 billion yuan since its IPO [2]. Product Development - The growth in performance is attributed to the stable sales of the key product, Peginterferon, which is a first-in-class drug with complete independent intellectual property rights [2]. - Teabo Bio has invested significantly in R&D, with expenditures rising from 76.68 million yuan in 2020 to 295 million yuan in 2024, totaling 833 million yuan over the five years [2]. Intellectual Property and Market Position - As of the end of 2024, Teabo Bio has obtained 16 invention patents and a total of 293 intellectual property rights [3]. - The company has made important progress in multiple R&D projects, including the acceptance of a drug registration application for its self-developed growth hormone injection in January 2024 [3]. Stock Performance - Teabo Bio's stock price has seen a significant increase, rising from an IPO price of 8.24 yuan per share to 78.96 yuan per share as of April 22, representing a cumulative increase of 858.25% [3].

4月22日晚间，特宝生物（688278.SH）交出了2025年第一季度报告。 对于净利润增长原因，特宝生物称，重点产品派格宾销售收入快速增长；同时总体费用率降低，盈利水 平提高。 报告显示，特宝生物第一季度营业收入为6.73亿元，同比增长23.48%；归母净利润为1.82亿元，同比增 长41.40%。 多家券商在近日发布的研报中表示看好派格宾带来的业绩增长。如财信证券称，派格宾新增适应症及长 效生长激素获批在即，有望助力特宝生物业绩保持快速增长。 （文章来源：21世纪经济报道） 然而市场却并未买账，4月23日开盘，特宝生物股价低开低走，盘中一度跌超10%。 有投资者指出，特宝生物扣非净利润增速正在变慢，还有投资者认为业绩增速不及预期。 财务数据显示，特宝生物今年一季度扣非净利润为1.89亿元，去年同期为1.46亿元，同比增长28.81%， 而去年同期的增长率为42.90%。 南财快讯记者以投资者身份致电特宝生物，工作人员表示，不太了解投资者所讲的预期是基于哪种情况 做的测算。今年一季度和去年一季度对比，需要考虑集采价格的影响。江西集采从2024年5月中下旬开 始陆续执行，到今年一季度大部分地区都按照集采价格销 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688278 证券简称：特宝生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 □是 √否 (三)主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

Financial Performance - The company's operating revenue for Q1 2025 reached ¥673,345,118.05, representing a 23.48% increase compared to ¥545,302,286.89 in the same period last year[3] - Net profit attributable to shareholders was ¥182,128,916.89, a 41.40% increase from ¥128,807,591.33 year-over-year[3] - Basic earnings per share increased by 40.63% to ¥0.45, compared to ¥0.32 in the same period last year[3] - Total operating revenue for Q1 2025 reached ¥673,345,118.05, a 23.5% increase from ¥545,302,286.89 in Q1 2024[16] - Net profit for Q1 2025 was ¥182,128,916.89, representing a 41.3% increase compared to ¥128,807,591.33 in Q1 2024[17] Cash Flow and Assets - The net cash flow from operating activities surged by 162.81%, amounting to ¥206,740,177.80, up from ¥78,663,848.24 in the previous year[3] - The company's cash and cash equivalents amounted to RMB 528,072,404.71, up from RMB 371,821,698.43, indicating a significant increase of about 42.03%[12] - Total assets at the end of the reporting period were ¥3,179,123,636.38, a 4.22% increase from ¥3,050,414,835.58 at the end of the previous year[4] - The total assets of the company rose to ¥3,179,123,636.38 in Q1 2025 from ¥3,050,414,835.58 in Q1 2024, marking an increase of 4.2%[15] - The company reported a cash outflow of CNY 614,579,315.86 from operating activities, which is an increase from CNY 550,264,204.09 in the previous year[19] Research and Development - Research and development expenses totaled ¥77,188,385.02, marking a 38.77% increase from ¥55,622,956.59 in the previous year, accounting for 11.46% of operating revenue[3] - Research and development expenses for Q1 2025 were ¥66,748,824.30, up 53.3% from ¥43,575,928.52 in Q1 2024, indicating a strong focus on innovation[16] Shareholder Information - The company reported a total of 7,468 common shareholders at the end of the reporting period[6] - The top shareholder, Yang Ying, holds 33.94% of the shares, totaling 138,077,266 shares[7] Community and Health Initiatives - The company has committed to additional donations totaling RMB 8 million for various hepatitis-related projects, with RMB 4 million already disbursed by the end of the reporting period[9] - The company has also donated RMB 2.7 million for the "Oasis Project" aimed at reducing liver cancer incidence among hepatitis patients, with total donations reaching RMB 31 million by the end of the reporting period[10] - The company plans to continue its support for hepatitis research and treatment initiatives, with ongoing projects and additional funding commitments[11] - The company is actively involved in community health initiatives, contributing to various projects aimed at improving public health outcomes related to hepatitis[9] Liabilities and Equity - Total liabilities decreased to ¥429,839,424.62 in Q1 2025 from ¥497,098,543.83 in Q1 2024, a reduction of approximately 13.5%[14] - Total equity attributable to shareholders increased to ¥2,749,284,211.76 in Q1 2025 from ¥2,553,316,291.75 in Q1 2024, reflecting a growth of 7.7%[15] Inventory and Receivables - Accounts receivable decreased to RMB 654,023,595.24 from RMB 771,496,539.39, representing a decline of approximately 15.19%[12] - Inventory increased to RMB 285,459,731.42 from RMB 263,546,426.51, showing a growth of about 8.29%[13] Financial Management - The company reported a financial asset impairment loss of ¥779,811.54 in Q1 2025, compared to ¥127,378.79 in Q1 2024, highlighting increased caution in asset management[17] - Deferred income increased to ¥40,555,586.47 in Q1 2025 from ¥32,961,392.76 in Q1 2024, indicating growth in future revenue recognition[14]

特宝生物公告，2025年第一季度营收为6.73亿元，同比增长23.48%；净利润为1.82亿元，同比增长 41.40%。 ...

厦门特宝生物工程股份有限公司 2024 年年度股东大会的 法律意见书 上海市锦天城（深圳）律师事务所 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 关于 上海市锦天城（深圳）律师事务所 法律意见书 关于厦门特宝生物工程股份有限公司 2024 年年度股东大会的 上海市锦天城（深圳）律师事务所 法律意见书 致：厦门特宝生物工程股份有限公司 根据厦门特宝生物工程股份有限公司（以下简称"贵公司"或者"公司"） 的委托，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）等法律、行政法规以及《厦 门特宝生物工程股份有限公司章程》（以下简称"《公司章程》"）、《厦门特 宝生物工程股份有限公司股东大会议事规则》（以下简称"《股东大会议事规 则》"）的规定，上海市锦天城（深圳）律师事务所（以下简称"本所"）指派 律师列席了公司 2024 年年度股东大会（以下简称"本次股东大会"），现就公 司本次股东大会召开的有关事宜出具本法律意见书。 本所同意将本法律意见书随贵公司本次股东大会 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-016 厦门特宝生物工程股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 18 日 （二） 股东大会召开的地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 117 | | --- | --- | | 普通股股东人数 | 117 | | 2、出席会议的股东所持有的表决权数量 | 215,781,023 | | 普通股股东所持有表决权数量 | 215,781,023 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 53.04 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 53.04 | （四） 表 ...

Summary of Conference Call Company and Industry - The conference call primarily discusses **特保生物 (TeBao Bio)**, a company in the **pharmaceutical industry**, focusing on **clinical cures for hepatitis B** and related treatments. Key Points and Arguments 1. **Financial Performance**: - The company reported a **net profit of 828 million yuan**, a **49% increase year-over-year**. The **deducted net profit** was **827 million yuan**, reflecting a **42.73% growth**. This performance is attributed to the increasing recognition of their product, **派格宾 (Pegbivac)**, in the market and improved management efficiency, leading to a reduction in overall expense ratios and enhanced profitability [2][3][21]. 2. **Product Development**: - The company is focusing on **immunology and metabolic diseases**, with ongoing research and development projects. Notably, **Pegbivac** has received clinical trial approvals for new indications, including **clinical cure for hepatitis B** and applications in treating **thrombocytopenia** [3][11][14]. 3. **Clinical Trials and Regulatory Approvals**: - The company submitted an **NDA (New Drug Application)** for **Pegbivac** in March 2024, which is currently under review. This submission is significant as it is the first global NDA for a clinical cure for hepatitis B [5][10][11]. 4. **Market Penetration and Treatment Efficacy**: - The penetration rate of antiviral treatments remains low, indicating a substantial market opportunity. The company believes that as scientific understanding and treatment options improve, the acceptance and demand for hepatitis B treatments will increase [20][21][24]. 5. **Collaborations and Partnerships**: - The company has established collaborations with various organizations, including **九天生物 (Nine Sky Bio)**, to enhance its product pipeline and leverage advanced technologies in gene therapy and immunotherapy [14][25]. 6. **Future Outlook**: - The management expressed confidence in becoming a leader in the field of clinical cures for hepatitis B and related diseases. They anticipate continued growth in R&D investments aligned with project needs and market demands [11][37]. Other Important but Possibly Overlooked Content 1. **Sales Strategy**: - There is a focus on expanding the sales team in anticipation of product approvals, although the current hiring pace is cautious due to pending regulatory approvals [36]. 2. **Research and Development Focus**: - The company emphasizes that R&D investments will be driven by the need to solve clinical problems rather than merely increasing the number of projects. This strategic approach aims to ensure that resources are allocated effectively to high-potential areas [37]. 3. **Patient Engagement and Market Dynamics**: - The management highlighted the importance of educating patients and healthcare providers about the benefits of achieving clinical cures for hepatitis B, which could drive demand and acceptance in the market [30][32]. 4. **Long-term Vision**: - The company aims to address the broader population of hepatitis B patients, including those in non-active phases, by enhancing treatment options and improving patient outcomes through innovative therapies [29][31]. This summary encapsulates the critical insights from the conference call, reflecting the company's strategic direction, financial health, and market opportunities within the pharmaceutical industry.

证券代码：688278 证券简称：特宝生物 公告编号：2025-015 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司 关于参加 2024 年度科创板生物制品及 CXO 行业 集体业绩说明会的公告 重要内容提示： 会议召开时间：2025 年 4 月 23 日（星期三）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 16 日（星期三）至 4 月 22 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir@amoytop.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2025 年 3 月 28 日发布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经营 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-014 厦门特宝生物工程股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于2025年3月28日披露了关于召开2024年年度股东 大会的通知，公司拟于2025年4月18日14:00召开2024年年度股东大会，本次会议采用现场投票和网络投 票相结合的表决方式，具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《关于召开 2024年年度股东大会的通知》（公告编号：2025-013）。 特此公告。 厦门特宝生物工程股份有限公司 董事会 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、及时投票，公司拟使用上 证所信息网络有限公司（以下简称"上证信息"）提供的股东大会提醒服务，委托上证信息通过发送智能 短信等形式，根据股权登记日的股东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参 会邀请、议案情况等信息。投资者在收到 ...